Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab
- PMID: 19152970
- PMCID: PMC4784096
- DOI: 10.1016/j.jaci.2008.11.035
Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab
Figures
References
-
- Dimson OG, Giudice GJ, Fu C-L, Warren SJ, Janson MM, Fairley JA. Identification of a Potential Effector Function for IgE Autoantibodies in the Organ-Specific Autoimmune Disease Bullous Pemphigoid. J Invest Dermatol. 2003;120:784–788. - PubMed
-
- Fairley JA, Fu CL, Giudice GJ. Mapping the binding sites of BP180 IgE autoantibodies in bullous pemphigoid. J Invest Dermatol. 2005;125:467–472. - PubMed
-
- Zone JJ, Taylor T, Hull C, Schmidt L, Meyer L. IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. J Invest Dermatol. 2007;127:1167–1174. - PubMed
-
- Fairley JA, Burnett CT, Fu C-L, Larson DL, Fleming MG, Giudice GJ. A pathogenic role for IgE in autoimmunity: Bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. J Invest Dermatol. 2007;127:2605–2611. - PubMed
-
- Holgate ST, Djukananovic R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy. 2005;35:408–416. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
